US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Ophthalmology Market Research Reports & Industry Analysis

A portion of ophthalmology that resists change unlike some other specialties is the consumer reluctance to undertake a procedure that may have side effects associated with vision like refractive laser correction. Any side effects concerning eyes/vision is typically avoided as much as possible especially if there are other options.
Typically if the out-of pocket price for a life-enhancing procedure is within the budget of a consumer, the patient has a strong desire to get the procedure, and other factors are present that allow for it, the procedure is undertaken. In laser correction there has been skepticism which has diminished as more patients undertake the procedure with good results. While new ideas, breakthrough technologies, cost efficiencies, increased productivity,and new markets are the keys to growth and competitiveness, most people [work force; consumers; academics; politicians] are more confident in familiar environments. They will resist change unless their job, livelihood, or lifestyles are threatened.

This phenomenon is partly responsible for the trend toward closing solo and small group practices to join vision care networks. Though this experience exists more in general medical practices and some pecialties, ophthalmologists also face the threat of practitioners [osteopathic physicians, doctors of optometry] replacing eye MDs—an intrusion on their medical training, skills, and specialty. However increasing healthcare costs, and economic changes sometimes force shifts in the typical work pattern of healthcare providers. One example is a change that has happened in states across the U.S. allowing optometrists to diagnose and treat glaucoma.

RSS Feeds

Ophthalmology Industry Research & Market Reports

< prev 1    3  4  5  6  7  8  9  10  
Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application (General & Cosmetic Surgery, Cardiovascular, Cancer, Ophthalmology, Orthopedics) - Global Forecasts to 2019
9/23/2014 | published by: MarketsandMarkets
... at a CAGR of 9.6% from 2014 to 2019. Although mature markets (such as the U.S., Germany, France, and the U.K.) hold larger shares in the ablation technologies market in 2014, the Asia-Pacific region is ...  |  read more...
USD 4,650
Uveitis - Pipeline Review, H2 2014
8/31/2014 | published by: Global Markets Direct
... Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Global Cytomegalovirus Retinitis Market : 2014-2018
8/13/2014 | published by: TechNavio - Infiniti Research Ltd.
... Roche Ltd., Gilead Sciences Inc., Hospira Inc. and Shire plc. Other Prominent Vendors in the market are: Auritec Pharmaceuticals, Chimerix Pharmaceuticals, Isis Pharmaceuticals, pSivida and Sanofi. Commenting on the report, an analyst from TechNavio’s team ...  |  read more...
USD 2,500
Global Macular Edema Market : 2014-2018
7/7/2014 | published by: TechNavio - Infiniti Research Ltd.
... F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Alimera Sciences Inc., Allergan Inc., Ampio Pharmaceuticals Inc., iCo Therapeutics Inc.,Pfizer Inc., Santen Pharmaceutical Co. Ltd. Commenting on the report, an analyst from TechNavio’s ...  |  read more...
USD 2,500
Global Retinal Vein Occlusion Market : 2014-2018
7/23/2014 | published by: TechNavio - Infiniti Research Ltd.
... AG, F. Hoffmann-La Roche Ltd., Novartis AG and Regeneron Pharmaceuticals Inc. Other prominent vendors in the market are: Alimera Sciences, Bristol-Myers Squibb, NicOx, Santen Pharmaceutical and Valeant Pharmaceuticals. Commenting on the report, an analyst from ...  |  read more...
USD 2,500
Ophthalmics Partnering Terms & Agreements
8/1/2014 | published by: Current Partnering
... or development stage whereby the licensee obtains a right or an option right to license the licensors opthalmics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report ...  |  read more...
USD 1,995
Glaucoma Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... by value •Deals listed by company A-Z, industry sector, stage of development, technology type Glaucoma Partnering 2009-2014 provides understanding and access to the glaucoma partnering deals and agreements entered into by the worlds leading healthcare ...  |  read more...
USD 695
Global Ophthalmic Diagnostic Devices Market : 2014-2018
7/14/2014 | published by: TechNavio - Infiniti Research Ltd.
... Commenting on the report, an analyst from TechNavio’s team said: “The minimally invasive procedure, Laser Vision Correction, popularly called LASIK, has become extremely popular in the Healthcare industry. In the US alone, about 19 million ...  |  read more...
USD 2,500
Glaucoma - Pipeline Review, H2 2014
7/31/2014 | published by: Global Markets Direct
... Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Open-Angle Glaucoma - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Age-related Macular Degeneration Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... age-related macular degeneration partnering deals •Top age-related macular degeneration deals by value •Deals listed by company A-Z, industry sector, stage of development, technology type Age-related Macular Degeneration Partnering 2009-2014 provides understanding and access to the ...  |  read more...
USD 695
Conjunctivitis Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... by value •Deals listed by company A-Z, industry sector, stage of development, technology type Conjunctivitis Partnering 2009-2014 provides understanding and access to the conjunctivitis partnering deals and agreements entered into by the worlds leading healthcare ...  |  read more...
USD 695
Dry Eye Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... deals •Top dry eye deals by value •Deals listed by company A-Z, industry sector, stage of development, technology type Dry Eye Partnering 2009-2014 provides understanding and access to the dry eye partnering deals and agreements ...  |  read more...
USD 695
Ophthalmics Deals and Alliances of 2013
8/1/2014 | published by: Current Partnering
... during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. ...  |  read more...
USD 1,495
Retinal Degeneration - Pipeline Review, H1 2014
6/30/2014 | published by: Global Markets Direct
... therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Sustained Release Ocular Drug Delivery Systems Market, 2014-2024
4/8/2014 | published by: Roots Analysis
... Several barriers have to be overcome for successful ocular drug delivery. For example, dilution of a drug by tears, clearance of a drug by the lymphatic system of conjunctiva, drug permeation issues with respect to ...  |  read more...
USD 1,899
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
6/30/2014 | published by: Global Markets Direct
... Exudative) Macular Degeneration’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of ...  |  read more...
USD 2,000
Market Highlights: Italy Age-related Macular Degeneration – 2014
5/1/2014 | published by: Fore Pharma
... forecast in Italy. The research includes Italy Age-related macular degeneration market size estimates for 2013, market share forecast for six years to 2019, Age-related macular degeneration drugs market share, Age-related macular degeneration drugs sales estimates, ...  |  read more...
USD 990
Market Highlights: Japan Age-related Macular Degeneration – 2014
5/1/2014 | published by: Fore Pharma
... forecast in Japan. The research includes Japan Age-related macular degeneration market size estimates for 2013, market share forecast for six years to 2019, Age-related macular degeneration drugs market share, Age-related macular degeneration drugs sales estimates, ...  |  read more...
USD 990
Ophthalmic Drugs Market Forecast 2014-2024
6/16/2014 | published by: Visiongain
... you potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our 337-page report provides 198 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our ...  |  read more...
USD 3,004
Market Highlights: Europe Age-related Macular Degeneration – 2014
5/1/2014 | published by: Fore Pharma
... for Germany, France, Italy, Spain, and UK. The research includes Europe (Germany, France, Italy, Spain, and UK) Age-related macular degeneration market size estimates for 2013, market share forecast for six years to 2019, Age-related macular ...  |  read more...
USD 2,800
Dry Eye Syndrome: Clinical Trial Tracker
4/29/2014 | published by: Roots Analysis
... no cure for dry eye syndrome, but there are treatments to control its symptoms. The prevalence of dry eye syndrome primarily increases with age, and has an estimated incidence of 15% in persons over the ...  |  read more...
USD 799
Market Highlights: UK Cataract – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, cataract drugs market share, cataract drugs sales estimates, cataract drugs sales forecast, and cataract late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Germany Cataract – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, cataract drugs market share, cataract drugs sales estimates, cataract drugs sales forecast, and cataract late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Update: Age-Related Macular Degeneration Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... It covers emerging therapies for Age-Related Macular Degeneration in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating ...  |  read more...
USD 590
< prev 1    3  4  5  6  7  8  9  10